NR
NeuroSense Therapeutics Ltd.
NRSN · NASDAQ
$6.66 -4.79% (-$0.33)
1M -15.33%
Market Cap $11.9M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$3.66
45.0% downside
Current Price
$6.66
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NRSN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
-
N/A EV/EBITDA N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
57 /100
Average ROA 1,082.20%
Asset turnover 0.00x
ROIC 797.48%
Debt
0 /100
High Int. coverage -652.06x
Current ratio 0.31x
Net debt/EBITDA N/A
Stability
54 /100
Moderate EPS volatility 7.33%
Profitable years 0
Beta 1.58x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NRSN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Alon Ben-Noon
Employees
17
Headquarters
Herzliya
Upcoming events
02 DEC
Earnings
Upcoming earnings report